{"access":"open","annotations":"Peptyd, tkanka, dawca i typowanie HLA dawcy; z natury wieloalleliczny, wi\u0119c przypisanie do allelu wymaga dekonwolucji.","article":"/blog/modele-prezentacji-antygenu","cancer_slugs":["pan-cancer"],"details":"","doi":null,"formats":["CSV"],"hf":null,"huggingface":null,"kind":"dataset","license":"CC BY 4.0","modalities":["immunopeptidomics"],"models":[{"name":"NetMHCpan-4.1","note":"wieloalleliczne peptydomy tkankowe, rozpl\u0105tywane w trakcie treningu","role":"training","slug":"netmhcpan"},{"name":"MixMHCpred 3.0","note":"","role":"training","slug":"mixmhcpred"}],"name":"HLA Ligand Atlas","page":"/ai-oncology/datasets/hla-ligand-atlas","provider":"University of T\u00fcbingen (Rammensee / Walz groups)","size":{"items":90428,"notes_en":"29 tissue types from 21 donors \u2014 benign tissue, which is what makes it a reference for what is NOT tumour-specific","notes_pl":"29 rodzaj\u00f3w tkanek od 21 dawc\u00f3w \u2014 tkanki prawid\u0142owe, co czyni go punktem odniesienia dla tego, co NIE jest swoiste dla guza","unit":"class I ligands"},"slug":"hla-ligand-atlas","sources":[{"label":"Marcu A et al. HLA Ligand Atlas. J Immunother Cancer 2021","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8054196/"}],"summary":"Referencyjny peptydom tkanek prawid\u0142owych: zbi\u00f3r, z kt\u00f3rym sprawdza si\u0119 kandydata na neoantygen, \u017ceby upewni\u0107 si\u0119, \u017ce zdrowa tkanka te\u017c go nie wystawia.","tasks":["antigen-presentation"],"url":"https://hla-ligand-atlas.org/","verified_at":"2026-09-05T22:25:59.165582"}